Welcome to our dedicated page for Nextcure news (Ticker: NXTC), a resource for investors and traders seeking the latest updates and insights on Nextcure stock.
NextCure, Inc. (NYSE: NXTC) is a clinical-stage biopharmaceutical company pioneering novel immunotherapies for cancer and immune disorders. This page provides centralized access to official news and developments surrounding their innovative pipeline, including antibody-drug conjugates and fusion protein therapies targeting complex tumor microenvironments.
Investors and researchers will find timely updates on clinical trial progress, strategic collaborations, and regulatory milestones. Key focus areas include NC410 combination therapies for immune modulation and the B7-H4-targeting LNCB74 ADC program. The curated news collection also covers financial disclosures, manufacturing advancements, and scientific presentations.
All content is sourced directly from company releases and verified industry publications. Bookmark this page to monitor NextCure's progress in developing first-in-class immunomedicines and their expanding research into neurodegenerative and chronic disease applications.
NextCure (NASDAQ: NXTC) has published a paper detailing the development of an immunohistochemical assay for Siglec-15, a protein implicated in cancer's immunosuppressive environment. This research, conducted with Yale School of Medicine, presents data supporting the targeting of Siglec-15 in therapeutic candidates like NC318. The study shows high S15 expression in non-small cell lung cancer (NSCLC), indicating a potential pathway for future clinical trials. The assay's validation and scoring system hold promise for advancing patient selection in ongoing trials.
NextCure (NASDAQ: NXTC) presented promising data on NC410 at the 2022 ECM Pharmacology Congress in Copenhagen, showcasing its ability to remodel tumor extracellular matrix (ECM), enhance immune cell infiltration, and reduce tumor growth in humanized mouse models. This first-in-class immunomedicine targets LAIR-1, overcoming barriers to immunotherapy. Highlights include NC410's binding to collagen-rich areas and synergistic effects with PD-L1 targeting. Currently in a Phase 1/2 study for advanced solid tumors, NextCure anticipates updates in late 2022.
NextCure, Inc. (Nasdaq: NXTC) announced research findings on NC410, an immunomedicine that blocks neutrophil-mediated T cell suppression in the tumor microenvironment (TME). Presented at the 24th TRCCC Annual Meeting, these findings highlight NC410's potential to enhance T cell responsiveness in ovarian cancer. The research suggests that LAIR-1 engagement by NC410 could play a crucial role in overcoming immune suppression. Dr. Brahm Segal was appointed to NextCure's Scientific Advisory Board, indicating a strategic partnership for advancing NC410's development.
NextCure, a clinical-stage biopharmaceutical company focused on developing innovative immunomedicines for cancer and immune-related diseases, will participate in a fireside chat at the JMP Securities Life Sciences Conference on June 15, 2022, at 2 PM ET. The session will be available via live audio webcast on NextCure's website, with a replay accessible for 30 days post-event. NextCure utilizes its proprietary FIND-IO™ platform to discover new therapeutic targets for patients who do not respond to existing cancer therapies.
NextCure (NASDAQ: NXTC) reported its first quarter 2022 financial results, revealing a cash position of $201.3 million expected to fund operations into Q1 2024. The company is advancing its pipeline with updates anticipated for NC318, NC410, and NC762 in the second half of 2022, alongside an IND filing for NC525. However, the company faced a net loss of $20.6 million, increased R&D expenses of $15.0 million, and a decrease in cash from $219.6 million at the end of 2021.
NextCure, a clinical-stage biopharmaceutical company, announced its participation in the BofA Securities 2022 Healthcare Conference in Las Vegas on May 10 at 10:40 am PT. The event will feature a fireside chat accessible via a live audio webcast on the company's website, with a replay available for 30 days post-event. NextCure focuses on developing first-in-class immunomedicines targeting cancer and immune-related diseases, utilizing its proprietary FIND-IO™ platform to identify novel targets for new treatments.
NextCure, Inc. (Nasdaq: NXTC) announced the publication of a paper in the Journal of Clinical Investigation detailing a preclinical study on the tumor microenvironment's role in cancer treatment. The study, in collaboration with the National Cancer Institute, demonstrated that targeting collagens via LAIR-1 and TGF-β signaling improved immune activation in murine models, resulting in high cure rates for colon and mammary carcinoma. CEO Sol Langermann emphasized the superior results achieved by combining interventions, highlighting the potential of their immunomedicine NC410 to treat multiple cancer types.
NextCure, a clinical-stage biopharmaceutical company (Nasdaq: NXTC), will present at the 21st Annual Needham Virtual Healthcare Conference on April 12 at 3 pm ET. The event will be accessible via a live audio webcast on their website, with a replay available for 30 days. NextCure focuses on developing first-in-class immunomedicines targeting cancer and immune-related diseases through its FIND-IO platform.
They aim to provide new treatment options for patients unresponsive to current therapies.
NextCure, Inc. (Nasdaq: NXTC) reported its financial results for Q4 and FY 2021, ending with a cash position of $219.6 million expected to fund operations into Q1 2024. The company aims for multiple data readouts in 2022 for its clinical programs: NC318, NC410, and NC762. Notably, NC318 showed potential benefits in patients with various cancers. The company faced operational delays due to COVID-19 but anticipates updates on its programs later this year.
NextCure, Inc. (Nasdaq: NXTC) announced its participation in the 11th Annual SVB Leerink Global Healthcare Conference on February 16 at 10:40 am ET. The conference will provide insights into the company's innovative treatments for cancer and immune-related diseases using their FIND-IO™ platform.
Additionally, a live audio webcast will be available on NextCure's website, with a replay accessible for 30 days post-event.
FAQ
What is the current stock price of Nextcure (NXTC)?
What is the market cap of Nextcure (NXTC)?
